AI Article Synopsis
- Immunotherapy, originally used for blood-related diseases, is now proving effective for solid tumors like melanoma and prostate cancer, but its effectiveness for breast cancer remains underexplored.
- Despite a lack of thorough evaluation, evidence suggests that immunotherapy could be a promising strategy for aggressive forms of breast cancer, given their high mortality rates.
- The text reviews recent immune-based therapies, focusing on immune checkpoint inhibitors, novel vaccine strategies, and the most significant immunotherapeutic techniques with potential implications for breast cancer treatment.
Article Abstract
Because its original use as a treatment for hematologic disease, more recently immunotherapy has emerged as a novel effective therapeutic strategy for solid malignancies, such as melanoma and prostate carcinoma. For breast carcinoma, an immunologic therapeutic approach has not been well evaluated, even though there is evidence to suggest it would be a successful novel strategy, especially taking into account the high mortality rate of the most aggressive variants of this heterogeneous disease. Here, we briefly describe the most recently awarded immune-based therapies with a consolidated or potential implication for the treatment of solid malignancies. We focus on immune checkpoints and on the clinical potential of their abrogation, with a further overview of novel vaccine-based approaches and the most relevant immunotherapeutic techniques. We aim to provide an exhaustive review of the most promising immune-therapeutic agents that may have implications for breast cancer treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1586/14737140.2015.1042864 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!